To see, or not to see, that is the question: can public disclosure really improve transparency between medicine and the pharmaceutical industry?
Australas Psychiatry
; 22(3): 281-284, 2014 Jun.
Article
in En
| MEDLINE
| ID: mdl-24696411
ABSTRACT
OBJECTIVE:
To critically review the potential effect of the public reporting of pharmaceutical company payments to healthcare professionals on the relationship between medicine and industry.METHOD:
This review is based on an examination of the 'Transparency Model' put out recently for consultation by Medicines Australia.RESULTS:
Public reporting in itself will neither sharpen the boundaries between medicine and the pharmaceutical industry nor restore public confidence.CONCLUSIONS:
Focusing on payments for clinical research and on the larger payments to healthcare professionals would lead to a better understanding of the interplay between science and marketing.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Australas Psychiatry
Journal subject:
PSIQUIATRIA
Year:
2014
Document type:
Article